AR058561A1 - Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco - Google Patents

Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco

Info

Publication number
AR058561A1
AR058561A1 ARP060105618A ARP060105618A AR058561A1 AR 058561 A1 AR058561 A1 AR 058561A1 AR P060105618 A ARP060105618 A AR P060105618A AR P060105618 A ARP060105618 A AR P060105618A AR 058561 A1 AR058561 A1 AR 058561A1
Authority
AR
Argentina
Prior art keywords
substances
rapamycin
control
cci
pharmaco
Prior art date
Application number
ARP060105618A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38050882&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058561(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR058561A1 publication Critical patent/AR058561A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se provee un método para preparar una composicion de rapamicina que posea una mayor potencia. El método involucra seleccionar un compuesto de rapamicina que posea menos de 1,5% de impurezas de rapamicina oxidativas e hidrolíticas y formular la rapamicina seleccionada con un antioxidante y excipientes opcionales. Reivindicacion 3: El método de acuerdo con la reivindicacion 1 o 2, en donde el antioxidante está seleccionado del grupo que consiste en un tocoferol, vitamina C, 2,6-di-terc- butil-4-metilfenol, y las mezclas de los mismos. Reivindicacion 13: El método de acuerdo con cualquiera de las reivindicaciones 1 a 12, en donde dicha rapamicina está seleccionada del grupo que consiste en rapamicina y CCI-779.
ARP060105618A 2005-12-20 2006-12-19 Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco AR058561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75218905P 2005-12-20 2005-12-20

Publications (1)

Publication Number Publication Date
AR058561A1 true AR058561A1 (es) 2008-02-13

Family

ID=38050882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105618A AR058561A1 (es) 2005-12-20 2006-12-19 Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco

Country Status (17)

Country Link
US (1) US20070142422A1 (es)
EP (1) EP1962819A1 (es)
JP (1) JP2009520818A (es)
KR (1) KR20080077989A (es)
CN (1) CN101340901A (es)
AR (1) AR058561A1 (es)
AU (1) AU2006331874A1 (es)
BR (1) BRPI0620213A2 (es)
CA (1) CA2632239A1 (es)
CR (1) CR10009A (es)
EC (1) ECSP088571A (es)
IL (1) IL191635A0 (es)
NO (1) NO20082446L (es)
PE (1) PE20071067A1 (es)
RU (1) RU2008121713A (es)
TW (1) TW200731967A (es)
WO (1) WO2007075621A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
US7563489B2 (en) * 2005-11-30 2009-07-21 Xerox Corporation Radiation curable phase change inks containing curable epoxy-polyamide composite gellants
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US20120237550A1 (en) * 2011-03-16 2012-09-20 Siemens Healthcare Diagnostics Inc. Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3104891A1 (en) * 2014-02-11 2016-12-21 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US546304A (en) * 1895-09-17 Shutter-hook
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
GB8803836D0 (en) * 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
GB2242080B (en) * 1990-03-09 1994-12-21 Krone Ag Electrical connectors
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2283344T3 (es) * 1999-10-29 2007-11-01 Kosan Biosciences, Inc. Analogos de la rapamicina.
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US6680330B2 (en) * 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
WO2003018573A1 (en) * 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
CN100402031C (zh) * 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
BRPI0412659A (pt) * 2003-07-16 2006-09-26 Wyeth Corp isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
WO2005016935A2 (en) * 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
US7202256B2 (en) * 2004-04-14 2007-04-10 Wyeth Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
US7622578B2 (en) * 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate

Also Published As

Publication number Publication date
KR20080077989A (ko) 2008-08-26
PE20071067A1 (es) 2007-11-26
IL191635A0 (en) 2009-02-11
US20070142422A1 (en) 2007-06-21
CA2632239A1 (en) 2007-07-05
JP2009520818A (ja) 2009-05-28
RU2008121713A (ru) 2010-01-27
CR10009A (es) 2008-09-23
NO20082446L (no) 2008-08-26
AU2006331874A1 (en) 2007-07-05
EP1962819A1 (en) 2008-09-03
CN101340901A (zh) 2009-01-07
TW200731967A (en) 2007-09-01
WO2007075621A1 (en) 2007-07-05
BRPI0620213A2 (pt) 2011-11-01
ECSP088571A (es) 2008-07-30

Similar Documents

Publication Publication Date Title
AR058561A1 (es) Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco
DOP2016000017A (es) Nuevos compuestos tricíclicos
FI3641819T3 (fi) Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
CL2018001031A1 (es) Inhibidores de ferroportina novedosos
ECSP066928A (es) Derivados de carbolina útiles en la inhibición de la angiogénesis
CU24400B1 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
CL2023001530A1 (es) Derivados espiráncos sustituidos de cadena lineal
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
CU20170085A7 (es) Derivados de imidazolidindiona para el tratamiento de la osteoartritis
GT200500310A (es) Compuestos organicos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
UY37971A (es) Derivados de indol macrocíclicos sustituidos
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
AR071762A1 (es) Derivados 5-hidroximetil-oxazolidin-2-ona para el tratamiento de enfermedades intestinales bacteriales
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
ECSP045277A (es) Composición oftálmica que comprende ascomicina
ECSP22027871A (es) COMPUESTOS HETEROC?CLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3
ES2497766T3 (es) Composiciones y procedimientos de sensibilizar a oxacilina Staphylococcus aureus resistente a meticilina
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
EP3781142A4 (en) NEW [1.1.1] BICYCLO COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure